Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in Anorexia Nervosa
NCT04878627Phase 1Active, not recruiting
- Sponsor
- University of California, San Diego
- Start
- Jan 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in anorexia nervosa (AN) comparing Cannabidiol with Placebo (2 arms). Primary endpoints: Committee of Clinical Investigations UKU-Side Effect Scale at 3 weeks, Blood tests for cannabinol (CBD) metabolites at 3 weeks and 1 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
cannabidiol
03
Conditions
anorexia nervosa (AN)
Beyond the preview
Go deeper on NCT04878627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04878627.